US Bankruptcy Chapter 11 Insolvency SEC Filings — August 28, 2026

Stalking horse bid from Teva at $57.5M upfront plus assumption of liabilities provides a valuation floor; contingent milestones up to $87.5M for IGALMI at-home use sNDA and commercial milestones create upside optionality for creditors

Appointment of Samir Saleem as Chief Restructuring Officer signals professional turnaround management, potentially maximizing creditor recoveries through auction process

Transaction must close by October 30, 2026, creating a defined catalyst timeline for auction results and court approval

Chapter 11 filing on June 23, 2026, with a stalking horse bid from PTC Therapeutics for ST-920 (Fabry gene therapy) indicates a structured exit, but undisclosed upfront consideration suggests weak negotiating leverage

Sale under Sections 105, 363, and 365 of Bankruptcy Code allows for a clean asset sale free of liens, potentially attracting higher bids in auction

No insider buying or selling reported in filings, indicating management is focused on restructuring rather than signaling conviction through personal trades

Strategic Process Committee of the Board formed to evaluate restructuring or sale transactions, providing governance oversight for value maximization

PTC Therapeutics as stalking horse buyer is a known entity in gene therapy, reducing execution risk for asset transfer

Zero revenue growth or operational metrics reported in filings, reflecting pre-revenue biotech status and high cash burn rates typical of Chapter 11 candidates

Contingent milestone payments of up to $67.5M for sNDA approval and $20M commercial milestones represent 152% upside over upfront, but are highly uncertain given regulatory and commercial risks

Stalking horse bid is subject to higher bids in auction; if no higher bid emerges, Teva may acquire assets at potentially undervalued price, disadvantaging unsecured creditors

Contingent milestone payments depend on FDA approval of IGALMI at-home use sNDA, which is uncertain and could be delayed or denied

Deal can be terminated by either party if not consummated by October 30, 2026, creating a hard deadline that could force fire-sale terms

Undisclosed upfront consideration for ST-920 sale raises concerns about distressed pricing; creditors may recover minimal value

Backup bidder may not emerge, leaving PTC as sole buyer with leverage to lower price or impose unfavorable terms

No cash position or debt levels disclosed in filings; both companies likely have minimal liquidity to fund operations through bankruptcy process

Absence of insider buying suggests management lacks confidence in recovery value or equity upside post-restructuring

Chapter 11 case in Delaware (Case No. 26-10989) may face delays due to court congestion or creditor objections, pushing timeline beyond expectations

Sale includes substantially all assets, leaving no ongoing business; shareholders likely receive zero recovery

Stalking horse bid at $57.5M sets a floor; if competing bidders emerge for IGALMI or other assets, final sale price could exceed $100M, benefiting creditors

Contingent payments up to $87.5M for sNDA and commercial milestones offer high-risk/high-reward for distressed debt investors if IGALMI gains FDA approval

ST-920 (Fabry disease) is a Phase 1/2 asset with potential; if auction attracts a strategic buyer like Pfizer or Sanofi, sale price could exceed PTC's bid

Unsecured debt trading at deep discounts (likely 10-20 cents on dollar) could yield 3-5x returns if asset sales exceed expectations

Samir Saleem's expertise in biotech restructurings may streamline process, reducing legal fees and preserving value for stakeholders

Section 363 sale allows buyer to acquire assets free of liens, reducing legal overhang and speeding closure, potentially attracting premium bids

Absence of insider selling suggests no panic dumping of equity, which could stabilize any over-the-counter trading post-filing

Teva's commercial infrastructure could accelerate IGALMI launch if sNDA approved, potentially unlocking milestone payments faster than standalone

Two biopharma companies (BioXcel, Sangamo) filed for Chapter 11 within two months, indicating a sector trend of cash-strapped pre-revenue biotechs liquidating assets via stalking horse auctions to repay debt

Both filings use stalking horse bids (Teva, PTC Therapeutics) as floor prices, suggesting buyers are dictating terms in distressed biotech M&A, with limited competitive bidding

Neither company reported revenue or operational metrics, highlighting that pre-revenue biotechs entering Chapter 11 offer zero equity value, with creditors relying solely on asset sale proceeds

No insider trading activity in either filing, contrasting with typical distressed situations where insiders often sell; this may reflect management focus on restructuring rather than personal trading

BioXcel's $87.5M in contingent payments tied to regulatory/commercial milestones is a rare feature in bankruptcy, offering potential upside for creditors if milestones are met

Both cases are in Delaware Bankruptcy Court, which handles majority of large Chapter 11 filings; court congestion could delay auctions and reduce asset values

Watch for higher bids in auction process; deadline for competing bids likely within 30-45 days of filing (late September 2026)

Bankruptcy Court hearing to approve sale order; expected in October 2026 before October 30 deadline

Watch for emergence of backup bidder for ST-920; auction likely in September 2026

Bankruptcy Court approval of Section 363 sale; expected in Q4 2026

FDA decision on at-home use sNDA could trigger milestone payments; no specific date disclosed but watch for regulatory updates

Watch for unsecured creditor committee formation and objections to sale terms, which could delay or modify transactions

Expected after court approval; watch for closing conditions and any price adjustments

If deal not consummated by this date, either party can terminate, risking collapse of sale and liquidation